Decitabine-induced DNA methylation-mediated transcriptomic reprogramming in human breast cancer cell lines; the impact of DCK overexpression

• Main Authors: Verona Buocikova (Author), Silvia Tyciakova (Author), Eleftherios Pilalis (Author), Chara Mastrokalou (Author), Maria Urbanova (Author), Miroslava Matuskova (Author), Lucia Demkova (Author), Veronika Medova (Author), Eleonora Marta Longhin (Author), Elise Rundén-Pran (Author), Maria Dusinska (Author), Ivan Rios-Mondragon (Author), Mihaela Roxana Cimpan (Author), Alena Gabelova (Author), Andrea Soltysova (Author), Bozena Smolkova (Author), Aristotelis Chatziioannou (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Decitabine (DAC), a DNA methyltransferase (DNMT) inhibitor, is tested in combination with conventional anticancer drugs as a treatment option for various solid tumors. Although epigenome modulation provides a promising avenue in treating resistant cancer types, more studies are required to evaluate...